Special Issue

Signal Peptides in Health and Disease: Molecular Mechanisms and Therapeutic Potential

Message from the Guest Editor

This Special Issue aims to compile innovative research and comprehensive reviews that explore the biological significance, mechanistic diversity, and translational potential of signal peptides.

We cordially invite authors to submit original research or review articles in this exciting area of biomedical research in order to enhance current knowledge on the molecular mechanisms via which signaling peptides influence protein trafficking, folding, and function, as well as their dysregulation in pathological conditions such as cancer, neurodegeneration, metabolic disorders, inflammation, and infectious diseases.

The scope of this Special Issue includes, but is not limited to, the following topics:

- Current knowledge regarding signal peptides;
- Novel signal peptide sequences and their functional characterization;
- Signal peptide mutations and their role in genetic diseases;
- Signal peptide-targeted drug delivery systems;
- Computational prediction and modeling of signal peptides;
- Signal peptides in host–pathogen interactions;
- Engineering of synthetic signal peptides for therapeutic applications.

Guest Editor

Dr. Renata Perlikowska

Department of Biomolecular Chemistry, Medical University of Lodz, Lodz, Poland

Deadline for manuscript submissions

31 January 2026

Biomedicines

About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:
indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:
JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:
manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).